// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB2 or Reference Infliximab

Josef S. Smolen - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Methotrexate

Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials

Atul A. Deodhar - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

LY2439821

Real-Life Treatment Strategies for Systemic Sclerosis According to Experts

Andreu Fern�ndez-Codina - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study

B Haraoui - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Abatacept

Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

Maria A. Lopez-Olivo - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo

Peter Nash - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study

Kimberly Morishita - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Response to JAK1/2 Inhibition with Baricitinib in “Candle”, “Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN-Mediated Autoinflammatory Diseases

Gina A. Montealegre Sanchez - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Baricitinib

Responsiveness and Minimally Clinically Important Differences of Promis Measures in Rheumatoid Arthritis

Susan J. Bartlett - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®

Denis Choquette - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adalimumab

Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study

Anthony So - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Glucocorticoid

Risk of Preterm Delivery Associated with Perinatal Exposure to Dmards in Women with Inflammatory Arthritis: A Population-Based Cohort Study

Nicole W. Tsao - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Penicillamine

Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients

Xavier Puchal - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment

Rohan Machhar - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period

Regan Arendse - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Ustekinumab

Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial

Roy Fleischmann - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

Interleukin

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study

Peter Nash - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

Tasocitinib

Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence

Ayano Kelly - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis

Fanxing Zeng - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study

Laura C Coates - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

secukinumab

Copyright © 2026. QuantiNova All rights reserved